CoChat

New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease

Open access
Musso, Giovanni, De Michieli, Franco, Bongiovanni, Daria, Parente, Renato, Framarin, Luciana, Leone, Nicola, Berrutti, Mara, Gambino, Roberto, Cassader, Maurizio, Cohney, Solomon, Paschetta, Elena · 2017 · Clinical Gastroenterology and Hepatology
Cited by 38

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

&NA; Epidemiologic data show an association between the prevalence and severity of nonalcoholic fatty liver disease and the incidence and stage of chronic kidney disease (CKD); furthermore, nonalcoholic steatohepatitis (NASH)‐related cirrhosis has a higher risk of renal failure, a greater necessity for simultaneous liver‐kidney transplantation, and a poorer renal outcome than cirrhosis of other etiologies even after simultaneous liver‐kidney transplantation. These data suggest that NASH and CKD share common proinflammatory and profibrotic mechanisms of progression, which are targeted incompletely by current treatments. We reviewed therapeutic approaches to late preclinical/early clinical stage of development in NASH and/or CKD, focusing on anti‐inflammatory and antifibrotic treatments, which could slow the progression of both disease conditions. Renin inhibitors and angiotensin‐converting enzyme‐2 activators are new renin‐angiotensin axis modulators that showed incremental advantages over angiotensin‐converting enzyme inhibitors/angiotensin‐receptor blockers in preclinical models. Novel, potent, and selective agonists of peroxisome proliferator‐activated receptors and of farnesoid X receptor, designed to overcome limitations of older compounds, showed promising results in clinical trials. Epigenetics, heat stress response, and common effectors of redox regulation also were subjected to intensive research, and the gut was targeted by several approaches, including synbiotics, antilipopolysaccharide antibodies, Toll‐like receptor‐4 antagonists, incretin mimetics, and fibroblast growth factor 19 analogs. Promising anti‐inflammatory therapies include inhibitors of NOD‐like receptor family, pyrin domain containing 3 inflammasome, of nuclear factor‐&kgr;B, and of vascular adhesion protein‐1, chemokine antagonists, and solithromycin, and approaches targeting common profibrogenic pathways operating in the liver and the kidney include galectin‐3 antagonists, and inhibitors of rho‐associated protein kinase and of epidermal growth factor activation. The evidence, merits, and limitations of each approach for the treatment of NASH and CKD are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2016.08.002

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

Metadata

Authors
Musso, G., De Michieli, F., Bongiovanni, D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Gambino, R., Cassader, M., Cohney, S., & Paschetta, E.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2017-07
Volume
15
Issue
7
Pages
972-985
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2511572965
Cited by
38
References
16
FWCI
4.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.